Thomas Keuer - ARCA Biopharma Chief Officer
Executive
Mr. Thomas Keuer is Chief Operating Officer of the Company. Mr. Keuer was ARCAs Executive Vice President, Pharmaceutical Operations for the past 8 years. Prior to joining ARCA, Mr. Keuer served in a number of senior leadership positions in the biopharmaceutical industry including SVP of Operations for Insmed, Inc., VP of Engineering for Baxter Healthcare, and VP of Operations for Somatogen, Inc since 2014.
| Age | 65 |
| Tenure | 10 years |
| Phone | 720 940 2200 |
| Web | https://www.arcabio.com |
ARCA Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1435) % which means that it has lost $0.1435 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2005) %, meaning that it created substantial loss on money invested by shareholders. ARCA Biopharma's management efficiency ratios could be used to measure how well ARCA Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.ARCA Biopharma currently holds 280 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. ARCA Biopharma has a current ratio of 16.63, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ARCA Biopharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ling Zhou | Adagene | N/A | |
| Graeme Currie | Pasithea Therapeutics Corp | 57 | |
| Lindsay Young | Tempest Therapeutics | N/A | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| MS MBA | Rezolute | 50 | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Steven CPA | NextCure | 61 | |
| Sanjeev Khindri | Aerovate Therapeutics | N/A | |
| Gopal MBBS | Rezolute | N/A | |
| Sebastien Maloveste | NextCure | N/A | |
| BSc MD | Aerovate Therapeutics | N/A | |
| Ami Knoefler | Adagene | N/A | |
| Michael Deperro | Rezolute | N/A | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| MaryAlice JD | Acrivon Therapeutics, Common | 50 | |
| Joshua JD | AN2 Therapeutics | 46 | |
| Jiping MD | Adagene | N/A | |
| Udayan MD | NextCure | N/A | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 |
ARCA Biopharma Management Team
Elected by the shareholders, the ARCA Biopharma's board of directors comprises two types of representatives: ARCA Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ARCA. The board's role is to monitor ARCA Biopharma's management team and ensure that shareholders' interests are well served. ARCA Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ARCA Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Ozeroff, Sr. VP, General Counsel and Secretary | ||
| Thomas Keuer, Chief Officer | ||
| Jeffrey CPA, Chief Officer |
ARCA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ARCA Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | 393.23 M | |||
| Shares Outstanding | 14.51 M | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 98.80 % | |||
| Number Of Shares Shorted | 4.99 M | |||
| Price To Earning | (0.63) X | |||
| Price To Book | 13.09 X | |||
| EBITDA | (7.3 M) |
Pair Trading with ARCA Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against ARCA Stock
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in ARCA Stock
If you are still planning to invest in ARCA Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ARCA Biopharma's history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |